SCHEMBL4836841

SCHEMBL4836841

CCCC(CCC)C(=O)N1CCc2ccccc2C1CCN1CCC(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.56
CCR2 P41597 5/20 0.49
HDAC1 Q13547 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CHRM4 P08173 1/20 0.41
DRD4 P21917 1/20 0.41
GRM2 Q14416 1/20 0.41
CCR5 P51681 2/20 0.40
UBE2M P61081 2/20 0.40
DCUN1D1 Q96GG9 2/20 0.40
OPRD1 P41143 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4837265 0.94 DRD2 (0.55) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4830129 0.86 DRD2 (0.53) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4833147 0.85 DRD2 (0.49) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4839076 0.84 DRD2 (0.51) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4841324 0.83 DRD2 (0.49) DRD2HDAC1HDAC8MEN1KMT2A
SCHEMBL4839067 0.83 NPSR1 (0.49) DRD2HDAC1HDAC8MEN1KMT2A
SCHEMBL4837068 0.83 NPSR1 (0.49) DRD2HDAC1HDAC8MEN1KMT2A
SCHEMBL4837310 0.82 DRD2 (0.48) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4838912 0.82 DRD2 (0.46) DRD2CCR2HDAC1HDAC8MEN1
SCHEMBL4835932 0.81 DRD2 (0.47) DRD2HDAC1HDAC8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 DRD2 684/4885CCR2 2042/4885HDAC1 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.